Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 18, Issue 11, 1999, Pages 783-789

  Naber, K G ^a   Theuretzbacher, U ^b   Moneva Koucheva, G ^a   Stass H ^c  

^a Urologische Klinik   (Germany)

^b Antibiotic Center   (Austria)

^c BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; NALIDIXIC ACID;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD LEVEL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ESCHERICHIA COLI; FEMALE; HUMAN; INFECTION COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CONCENTRATING CAPACITY; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; SPECIES; URINARY EXCRETION; URINARY TRACT INFECTION;

EID: 0032803376     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050401     Document Type: Article

References (24)

1. Bergan T, Dalhoff A, Rohwedder R: Pharmacokinetics of ciprofloxacin. Infection (1988) 16, Supplement 1:3-13
2. Vance-Bryan K: Clinical pharmacokinetics of ciprofloxacin. Clinical Pharmacokinetics (1990) 19:434-461
3. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rational for antibacterial dosing of mice and men. Clinical Infectious Diseases (1998) 26:1-12
4. Bannefeld KH, Staß H, Blaschke G: Capillary electrophoresis with laser-induced fluorescence detection, an adequate alternative to high-performance liquid chromatography, for the determination of ciprofloxacin and its metabolite desethyleneciprofloxacin in human plasma. Journal of Chromatography B (1997) 692:453-459
5. Naber KG, Witte W, Bauernfeind A, Wiedemann B, Grimm H: Resistenzentwicklung gegenüber Fluorchinolonen. Untersuchungen mit Erregern von Patienten mit komplizierten Harnwegsinfektionen. Chemotherapie Journal (1993) 2:106-111
6. Naber KG: Use of quinolones in urinary tract infections and prostatitis. Reviews of Infectious Diseases (1989) 11, Supplement 5:1321-1337
7. Shah A, Lettieri J, Blum R, Millikin S, Sica D, Heller AH: Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects. Journal of Antimicrobial Chemotherapy (1996) 38:103-116
8. Drobot GR, Karlowsky JA, Hoban DJ, Zhanel GG: Antibiotic activity in microbiological media versus that in human urine: comparison of ampicillin, ciprofloxacin, and trimethoprim-sulfamethoxazole. Antimicrobial Agents and Chemotherapy (1996) 40:237-240
9. Gesu GP, Eftimiadi C, Debbia E, Schito GC: Effects of changes in pH, medium and inoculum size on the in vitro activity of different quinolone and fluoroquinolone antibiotics against urinary pathogens. Drugs Under Experimental and Clinical Research (1987) 13:79-84
10. Leigh DA, Tait S, Walsh B: Antibacterial activity of lomefloxacin. Journal of Antimicrobial Chemotherapy (1991) 27:589-598. Erratum: Journal of Antimicrobial Chemotherapy (1991) 28:481
11. Norrby SR: Treatment of urinary tract infections with quinolone antimicrobial agents. In: Hooper DC, Wolfson JS (eds): Quinolone antimicrobial agents. American Society for Microbiology, Washington DC (1993) pp 273-283
12. Naber K, Theuretzbacher U, Kinzig M, Savov O, Sörgel F: Urinary excretion and bactericidal activity following a single oral dose of 400 mg fleroxacin versus 800 mg pefloxacin in healthy volunteers. Antimicrobial Agents and Chemotherapy (1998) 42:1659-1665
13. Zhanel GG, Karlowsky JA, Davidson RJ, Hoban DJ: Influence of human urine on the in vitro activity and postantibiotic effect of ciprofloxacin against Escherichia coli. Chemotherapy (1991) 37:218-223
14. Aagaard J, Gasser T, Rhodes P, Madsen PO: MICs of ciprofloxacin and trimethoprim for Escherichia coli: influence of pH, inoculum size and various body fluids. Infection (1991) 19, Supplement 3:167-169
15. Drobot GR, Karlowsky JA, Hoban DJ, Zhanel GG: Antibiotic activity in microbiological media versus that in human urine: comparison of ampicillin, ciprofloxacin, and trimethoprim-sulfamethoxazole. Antimicrobial Agents and Chemotherapy (1996) 40:237-240
16. Zeiler MJ, Beerman D, Wingender W, Föster D, Schacht P: Bactericidal activity of ciprofloxacin, norfloxacin, and ofloxacin in serum and urine after oral administration to healthy volunteers. Infection (1988) 16, Supplement 1:19-23
17. Naber KG: Antibacterial activity of antibacterial agents in urine: an overview of applied methods. In: Bergan T (ed): Urinary tract infections. Infectiology. Karger, Basel (1997) pp 74-83
18. Naber KG: The bactericidal activity of gatifloxacin in plasma and urine. Clinical Microbiology and Infection (1998) 4:731
19. Israel D, Gillum JG, Turik M, Harvey K, Ford J, Dalton H, Towle M, Echols R, Heller AH, Polk R: Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrobial Agents and Chemotherapy (1993) 37:2193-2199
20. Schentag JJ: The antimicrobial efficacy of intravenous ciprofloxacin in severe infection. Infection in Medicine (1992) 9, Supplement B: 41-57
21. Krcmery S, Naber RG, German Ciprofloxacin UTI Study Group: Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections. International Journal of Antimicrobial Agents (1999) 11:133-138
22. Weinstein MP, Stratton CW, Ackley A, Hawley HB, Robinson PA, Fisher BD, Alcid DV, Stevens DS, Reller LB: Multicenter collaborative evaluation of a standardized bactericidal test as a prognostic indicator in infective endocarditis. American Journal of Medicine (1985) 78:262-269
23. Wise R, Andrews JM: The bactericidal activity of gatifloxacin on plasma and urine. Clinical Microbiology and Infection (1998) 4:392-396
24. Goto T, Nakame Y, Nishida M, Ohi Y: Bacterial biofilms and catheters in experimental urinary tract infection. International Journal of Antimicrobial Agents (1999) 11:227-231